News and Events
A Shot In The Arm
05 May 2014
05 May 2014
At present, the company has around 500 employees Bharadwaj says they are now poised for the next phase of growth, saying, “Anthem literally
means a song of celebration and that is what we intend to achieve.
Biospectrum Entrepreneur of the Year
05 Dec 2013
05 Dec 2013
"Our CEO & Founder, Ajay Bhardwaj received the "Entrepreneur of the Year Award", from Biospectrum for the year 2013 . This Award is a celebration for each and every employee of Anthem. Under the able leadership and guidance of Ajay Bhardwaj and hard work put in by the employees, this achievement has been possible. "
South America, an important market of the future
01 Aug 2013
01 Aug 2013
South America, especially Brazil and Argentina avree ry important markets for India in the future. Dpeitse the mammoth presence of the multinational comanpies, Indian
pharmaceutical and biotechnology companies can make a big difference in Brazil in particular and Sou tAhmerican markets in general.
South America, an important market of the future
06 Aug 2013
06 Aug 2013
South America, especially Brazil and Argentaina are very important markets for india in the future. Despite the mammoth presence of the multinational companies, Indian pharmaceutical and biotechnology companies can make a big difference in Brazil in particular
SPIRIT OF ENTREPRENEURSHIP AJAY BHARADWAJ FOUNDER,ANTHEM BIOSCIENCES
18 June 2013
18 June 2013
Ajay Bharadwaj says 15 minutes in 2006 changed his life.He was
then president of marketing and technical services at Kiran
Mazumdar-Shaws Biocon,where he had spent 20 years playing a
central role in its transformation into a global biotechnology
company.He had reached a level where he thought he couldnt grow
any further.He could only move laterally.The company had become
big and all kinds of,
There is a huge contract research
outsourcing incline towards China rather
than India” 12 April 2013
Today, China has many positives; its infrastructure is a big plus and there are many incentives
that the Chinese government is offering to the pharma and biotech companies to come to China.
This clearly is a big deciding point for the companies of the West to go to China. More
importantly, most of the big pharma and biotech companies have been working with China for
the past decade or so and have invested a lot of capital.
Anthem Biosciences on accelerated mode in drug discovery, patents & partnerships
3 Apr 2013
3 Apr 2013
Anthem Biosciences is now scaling up the research ladder with three major initiatives. These include research on an oncology new chemical entity (NCE)in partnership with a US
company, development of a novel platform technology Genetox and development of chiral intermediates.
Anthem Biosciences to enter biopharma space 19 Mar 2013
Bangalore: India's custom research and drug discovery company Anthem Biosciences Pvt Ltd is planning
to invest Rs 1 billion to set up its second manufacturing plant at the Harohalli industrial area in Bangalore,
in a bid to enter bio-pharmaceuticals space, news portal Pharmabiz reported Tuesday, citing Chief
Executive Officer Ajay Bharadwaj.
Anthem infuses Rs.100 cr to get into bio-pharma products from its dedicated 2nd unit 19 Mar 2013
Anthem Group has planned an investment of Rs.100 crore to open its second production facility at the Harohalli Industrial Area in Bengaluru. The facility is coming up on a 15 acre area of the Karnataka Industrial Area Development Board (KIADB). The project was cleared by the Karnataka Udyog Mitra (KUM).
Anthem to expand its facility in Bengalure 10 Sept 2012
Anthem Biosciences, a Bengaluru - based Discovery Alliance Partner (DRAP) company dedicated to supporting research efforts in the discovery of new compounds by pharmaceutical, biotechnology
BioServices registers 15.5% growth 27 Jun 2012
The BioServices sector witnessed a growth of 15.5
percent in 2011-12 in spite of facing many issues
from the regulatory agencies. The sector touched a
revenue of 3,749 crore as against last year's revenue
of 3,246 crore. The drop in the growth rate over
previous year's growth rate was attributed to the
delays in getting approvals from the Drug Controller
General of India (DCGI) by the
A phase of consolidation in biopharma sector 23 June 2011
From doubling capacity of its research lab and pilot plant for biology and chemistry synthesis, Anthem Biosciences is now sprucing up its business game-plan to keep pace with
the rapidly changing market place , which is scouting for high quality domain expertise in research and production of biopharmaceuticals. In an interaction, Ajay Bharadwaj,
Chief Executive Officer & Founder, Anthem Biosciences provides an overview
Anthem Biosciences to commission its pilot plant, cGMP lab by July 18 June 2013
Anthem Biosciences, India's latest pharma-biotech start-up
venture is gearing up to commission its unit consisting of
GMP pilot plant, cGMP kilo lab and a full-fledged medicinal
chemistry department in July this year.
Anthem Biosciences eyes manufacturing 17 Jun 2011
Pharma and biotechnology contract research start-up Anthem Biosciences Ltd, which opened business less than five
years back, is readying to expand into manufacturing bulk intermediates and active drugs for clients soon.
There is good demand from overseas companies and those within the country for taking up such contracts and it would
be the next rung of growth for the company, said Mr Ajay Bharadwaj,
Anthem Biosciences on high pace growth
With the right business model and a planned strategy, Anthem Biosciences is well positioned to
benefit from the opportunities available in the contract research space. Having strong project
pipeline from large multinational pharmaceutical majors, the start up is all set to cross Rs 65 crore
in the current financial year.
Beneficial Bugs 2 Sep,2013
Probiotics are bacteria that are good for the human system. But only when consumed the correct way.
Ajay Bhardwaj.
Ajay Bhardwaj.